本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Allogene Therapeutics Inc.

1.24
+0.00500.41%
成交量:200.39万
成交额:250.59万
市值:2.78亿
市盈率:-1.26
高:1.28
开:1.22
低:1.21
收:1.23
52周最高:3.78
52周最低:0.8621
股本:2.25亿
流通股本:1.68亿
量比:0.97
换手率:1.19%
股息:- -
股息率:- -
每股收益(TTM):-0.9781
每股收益(LYR):-1.3222
净资产收益率:-54.43%
总资产收益率:-27.34%
市净率:0.88
市盈率(LYR):-0.93

数据加载中...

2024/05/14

重要事件披露

Form 8-K - Current report
2024/05/13

重要事件披露

Form 8-K - Current report
2024/05/13

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/04/24

SEC问询函

Form CORRESP - Correspondence
2024/04/23

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/03/14

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/03/14

年度报告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2024/03/14

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/03/14

重要事件披露

Form 8-K - Current report
2024/03/14

[修订]年度报告

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
2024/02/23

SEC问询函

Form CORRESP - Correspondence
2024/02/16

重要事件披露

Form 8-K - Current report
2024/02/15

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/14

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/14

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/01/31

重要事件披露

Form 8-K - Current report
2024/01/23

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/01/05

重要事件披露

Form 8-K - Current report
2023/12/20

重要事件披露

Form 8-K - Current report
2023/12/19

关联方拟减持公告

Form 144 - Report of proposed sale of securities